Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrating outcomes research into clinical practice.

Michael A Posternak1, Mark Zimmerman, David A Solomon

  • 1Department of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence 02905, USA. mposternak@lifespan.org

Psychiatric Services (Washington, D.C.)
|March 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stratification by Ki-67 Labeling Index Increases Specificity of p16<sup>INK4a</sup> Expression as a Surrogate Marker for CDKN2A Inactivation in Meningioma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Born of rosettes, fueled by fusion-Astroblastoma blasts off.

Neuro-oncology·2026
Same author

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases.

Neuro-oncology·2026
Same author

Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma.

JCI insight·2025
Same author

PLAG1 fusions define a third subtype of CNS embryonal tumor with PLAG family gene alteration.

Acta neuropathologica·2025

This study followed 102 major depressive disorder patients for two years. Brief instruments effectively measured symptom changes, showing recovery times similar to national studies.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Mental Health Research

Background:

  • Major depressive disorder (MDD) is a prevalent mental health condition requiring effective outcome measurement.
  • Assessing treatment efficacy in routine psychiatric care is crucial for patient management.
  • Existing outcome measures may not always be suitable for frequent clinical use.

Purpose of the Study:

  • To evaluate the utility of brief symptom measurement instruments in a real-world clinical setting for major depressive disorder.
  • To assess the time to recovery in psychiatric outpatients with MDD using prospective ratings.
  • To compare recovery time data with findings from the National Institute of Mental Health's Collaborative Depression Study.

Main Methods:

  • A cohort of 102 psychiatric outpatients diagnosed with major depressive disorder was prospectively followed for approximately two years.

Related Experiment Videos

  • Symptom changes were measured at medication management visits using two distinct assessment instruments.
  • Data analysis focused on determining the mean time to recovery.

    • Main Results:

    • The mean time to recovery for patients in this cohort was found to be comparable to that reported in the National Institute of Mental Health's Collaborative Depression Study.
    • The study demonstrated that brief instruments could capture meaningful changes in depressive symptoms over time.
    • No significant deviations from established recovery benchmarks were observed.

    Conclusions:

    • The findings support the validity and reliability of employing brief instruments for outcome assessment in routine psychiatric clinical practice.
    • Using concise measurement tools can facilitate efficient monitoring of treatment progress for major depressive disorder patients.
    • This approach enhances the feasibility of outcome tracking within standard medication management visits.